Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Receivables (2016 - 2025)

Kiora Pharmaceuticals' Change in Receivables history spans 5 years, with the latest figure at $309544.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 126.18% year-over-year to $309544.0; the TTM value through Dec 2025 reached $921573.0, up 53.29%, while the annual FY2025 figure was $921573.0, 53.29% up from the prior year.
  • Change in Receivables reached $309544.0 in Q4 2025 per KPRX's latest filing, up from -$1.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.2 million in Q2 2024 to a low of -$1.2 million in Q3 2025.